{"nctId":"NCT00393458","briefTitle":"Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control","startDateStruct":{"date":"2006-10"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":1732,"armGroups":[{"label":"Indacaterol 300 μg plus placebo to formoterol","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Placebo to formoterol"]},{"label":"Indacaterol 600 μg plus placebo to formoterol","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Placebo to formoterol"]},{"label":"Formoterol 12 μg plus placebo to indacaterol","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Formoterol","Drug: Placebo to indacaterol"]},{"label":"Placebo to indacaterol plus placebo to formoterol","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo to indacaterol","Drug: Placebo to formoterol"]}],"interventions":[{"name":"Indacaterol","otherNames":[]},{"name":"Formoterol","otherNames":[]},{"name":"Placebo to indacaterol","otherNames":[]},{"name":"Placebo to formoterol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female adults ≥ 40 years, with a diagnosis of chronic obstructive pulmonary disease (COPD) according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2005 and:\n\n  1. Smoking history of at least 20 pack years\n  2. Post-bronchodilator forced expiratory volume in 1 second (FEV1) \\< 80% and ≥ 30% of the predicted normal value\n  3. Post-bronchodilator FEV1/FVC (forced volume capacity) \\< 70% (Post refers to within 30 minutes after inhalation of 400 μg of salbutamol)\n\n     Exclusion Criteria:\n* Patients who were hospitalized for a COPD exacerbation in the 6 weeks prior to screening.\n* Patients who had a respiratory tract infection within 6 weeks prior to screening.\n* Patients with concomitant pulmonary disease.\n* Patients with a history of asthma.\n* Patients with diabetes type I or uncontrolled diabetes type II.\n* Any patient with lung cancer or a history of lung cancer.\n* Patients with a history of certain cardiovascular co-morbid conditions.\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 + 1 Day, Day 85","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at the end of treatment. The analysis included baseline FEV1, FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.48","spread":"0.012"},{"groupId":"OG001","value":"1.48","spread":"0.013"},{"groupId":"OG002","value":"1.38","spread":"0.013"},{"groupId":"OG003","value":"1.31","spread":"0.013"}]}]}]},{"type":"SECONDARY","title":"Percentage of Days of Poor Control During 52 Weeks of Treatment","description":"Percentage of days of poor control was defined as the number of days in the patient diary with a score ≥ 2 (scale of 0-3, a higher number means more severe symptoms) for at least 2 of 5 symptoms (cough, wheeze, production of sputum, color of sputum, breathlessness) over 52 weeks divided by the number of evaluable days (days with ≥ 2 symptoms with scores). The analysis included baseline percentage of days of poor control, FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.6","spread":"1.43"},{"groupId":"OG001","value":"30.0","spread":"1.46"},{"groupId":"OG002","value":"33.5","spread":"1.45"},{"groupId":"OG003","value":"38.3","spread":"1.47"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":63,"n":437},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Upper respiratory tract infection bacterial","Cough","Lower respiratory tract infection"]}}}